Dublin, June 16, 2022 (GLOBE NEWSWIRE) -- The "Global Renal Denervation Market Size, Share & Industry Trends Analysis Report By Technology (Radiofrequency, Ultrasound, and Micro-Infusion), By End User, By Product Type By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
The Global Renal Denervation Market size is expected to reach $1.4 billion by 2028, rising at a market growth of 36.4% CAGR during the forecast period.
Renal denervation is a minimally invasive, catheter-based treatment for hypertension. The nerves in the renal arteries are burnt using radiofrequency ablation. Nerve activity is lowered, and blood pressure is reduced. When pharmacological treatment has failed to provide relief, this procedure is usually employed in order to obtain enhanced results. The nerves of the renal artery wall are ablated using radiofrequency pulses or ultrasound. This reduces blood pressure by lowering sympathetic kidney activity.
One of the key factors supporting Market growth is a significant rising prevalence of lifestyle diseases, like hypertension, due to an increase in the number of people who smoke and drink alcohol, sedentary and hectic lifestyles, increasing unhealthy dietary patterns, and the surging geriatric population. Apart from that, the RDN system's advantages, such as quick recuperation, safety, efficiency, and cost-effectiveness, are operating as a major growth-inducing element. Moreover, the rising demand for minimally invasive surgeries is fueling the Market 's expansion. In addition, micro-infusion technology, improved healthcare infrastructure, increased research and development activities, and an increase in the number of files for regulatory approvals of the systems are all contributing to Market expansion.
Ultrasound ablates nerves in the renal artery wall, interrupting nerve impulse transmission and decreasing blood pressure with ultrasound-based renal denervation devices. It is a hypertension treatment that is done with the least amount of invasiveness possible. Ultrasound-based technologies" significant efficacy in trials is anticipated to rise their relevance and rejuvenate them. For example, ReCor Medical, a medical device manufacturer, debuted Paradise Ultrasound Renal Denervation for the therapeutics of hypertension in October 2021. This minimally invasive renal denervation technology is used to treat excessive blood pressure. Hence, the significant number of benefits of this method along with the increasing efforts and initiatives being introduced by major Market players is expected to accelerate the growth of the renal denervation Market throughout the coming years.
COVID-19 Impact Analysis
The COVID-19 pandemic caused a severe impact on various economies all over the world. Several businesses were significantly devastated as a result of the outbreak of the COVID-19 infection. In addition, the governments of several countries were forced to impose lockdowns in their nations. As a result, the manufacturing units of numerous goods were temporarily shut down. Moreover, these lockdowns also caused a major disruption in the supply chain of various goods. Further, COVID-19 led the worldwide healthcare industry to a significant failure due to the shortage of beds and oxygen in hospitals.
Market Growth Factors
Rising instances of hypertension among people
With the increasing modernization all over the world, the lifestyles of people are majorly being altered. The day-to-day routines of people worldwide are increasingly becoming hectic. Hypertension is a significant and modifiable risk factor for cardiovascular disorders and diseases, chronic kidney disease, and death. Because more strict BP objectives are recommended by guidelines, obtaining these targets frequently necessitates the use of multiple drugs, which can result in increased dosing complexity, expense, pill burden, and drug intolerance. There are few choices for treating hypertension without worsening polypharmacy or in the presence of multidrug intolerance.
Introduction of new capabilities in Renal Denervation
The number of new capabilities that are being introduced in the renal denervation approach is one of the major factors that is accelerating its adoption. Renal denervation systems that incorporate ultrasound technology can overcome the limitations of radiofrequency-based renal denervation systems. The high-frequency sound waves of the ultrasonic energy aid to ablate nerves without coming into close touch with the tissues. This aids in the prevention of renal artery damage. Due to this attribute, a significant number of patients all over the world prefer this technology. Moreover, the integration of technology into these kinds of healthcare practices offers a considerable scale of enhancements in the outcomes of these techniques.
Market Restraining Factors
Risk of post-surgery infection
One of the major factors that are restricting the demand for renal denervation methods is the risk of infection that can be caused post a surgery. Any kind of surgery that involves cuts, incisions, or any other kind of invasion into the skin can cause infection in the body of the patient. Mostly, infections in surgical wounds are visible after one month of the surgery. Due to the post-surgical infection, various types of problems in the wound or in the body of the patient can occur. For example, surgical wound infections can ejaculate the puss from the incision. In addition, these infections are very painful and cause soars and inflammation in the wound.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
18.104.22.168 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Renal Denervation Market by Technology
3.1 Global Radiofrequency Market by Region
3.2 Global Ultrasound Market by Region
3.3 Global Micro-Infusion Market by Region
Chapter 4. Global Renal Denervation Market by End User
4.1 Global Hospitals Market by Region
4.2 Global Specialty Clinics Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Renal Denervation Market by Product Type
5.1 Global Symplicity Market by Region
5.2 Global Enlightn Market by Region
5.3 Global Vessix Market by Region
5.4 Global Paradise Market by Region
5.5 Global Iberis Market by Region
5.6 Global Others Market by Region
Chapter 6. Global Renal Denervation Market by Region
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Boston Scientific Corporation
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Medtronic PLC
7.3.1 Company overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
22.214.171.124 Partnerships, Collaborations, and Agreements:
7.4 Ablative Solutions, Inc.
7.4.1 Company Overview
7.5 Mercator MedSystems, Inc.
7.5.1 Company Overview
7.6 ReCor Medical, Inc (Otsuka Holdings Co., Ltd.)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
126.96.36.199 Product Launches and Product Expansions:
7.7 Renal Dynamics Limited
7.7.1 Company Overview
7.8 Johnson & Johnson
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental &Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
188.8.131.52 Partnerships, Collaborations and Agreements:
7.9 Terumo Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
184.108.40.206 Acquisition and Mergers:
For more information about this report visit https://www.researchandmarkets.com/r/f5d1sb
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900